BridgeBio Pharma (BBIO) Consolidated Net Income (2018 - 2026)

BridgeBio Pharma has reported Consolidated Net Income for 9 years, with the latest figure at -$120.0 million in Q1 2026.

• Quarterly Consolidated Net Income rose 1.83% year-over-year to -$120.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$683.3 million (down 8.56% YoY) and the FY2025 annual result came in at -$732.9 million, down 34.89% from the prior year.
• Consolidated Net Income climbed to -$120.0 million in Q1 2026 per BBIO's latest filing, from -$194.6 million in the prior quarter.
• Over five years, Consolidated Net Income peaked at -$35.0 million in Q1 2024 and troughed at -$267.4 million in Q4 2024.
• A 5-year average of -$154.4 million and a median of -$164.3 million in 2024 frame the typical range for Consolidated Net Income.
• The sharpest annual moves came in 2024 and 2025: Consolidated Net Income surged 76.34% in 2024, then slumped 249.3% in 2025.
• Over 5 years, Consolidated Net Income stood at -$145.1 million in 2022, then slumped by 39.39% to -$202.3 million in 2023, then tumbled by 32.17% to -$267.4 million in 2024, then gained by 27.23% to -$194.6 million in 2025, then soared by 38.32% to -$120.0 million in 2026.
• According to Business Quant data, Consolidated Net Income over the past three periods registered -$120.0 million, -$194.6 million, and -$184.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.